TOMZNasdaqIndustrial Organic ChemicalsUS GAAP · USD

TOMI Environmental Solutions, Inc.

TOMI Environmental Solutions, Inc. develops and commercializes disinfection and decontamination technologies for use in controlled environments and public spaces. Its business centers on hydrogen peroxide-based systems and related application methods sold into healthcare, life sciences, food safety, and other contamination-sensitive settings in the United States and international markets.

Liikevaihto5,6milj. USD
−27,2 %v/v
Liikevoitto (EBIT)−3,9milj. USD
+6,1 %v/v
EBIT-marginaali−68,4%
−15,3 %-yks.v/v
Nettotulos−3,7milj. USD
+16,3 %v/v
Vapaa kassavirta−1,2milj. USD
+22,4 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2020–2025

−100102030milj. USD2020: 25 milj. USD2020: EBIT 4,5 milj. USD20202021: 7,8 milj. USD2021: EBIT −4,9 milj. USD20212022: 8,3 milj. USD2022: EBIT −2,9 milj. USD20222023: 7,4 milj. USD2023: EBIT −3,3 milj. USD20232024: 7,7 milj. USD2024: EBIT −4,1 milj. USD20242025: 5,6 milj. USD2025: EBIT −3,9 milj. USD20255,6−3,9
LiikevaihtoLiikevoitto (EBIT)

Liiketoiminta

Osuus liikevaihdosta
Disinfection systems45 %

Equipment and systems used to apply TOMI's disinfection technology in rooms, surfaces, and enclosed spaces.

Consumables and accessories20 %

Replacement parts, consumables, and application components used with installed systems.

Service and decontamination work25 %

Direct disinfection, decontamination, and application services performed for customers.

Licensing and other revenue10 %

Other commercial arrangements tied to the company's proprietary technology and related offerings.

Asiakkaat

TOMI sells to organizations that need validated disinfection and contamination control, especially where hygiene standards are critical. Typical buyers include hospitals, laboratories, pharmaceutical and biotech facilities, food processing operators, and commercial or institutional users that need repeatable room and surface treatment.

Healthcare

Hospitals and clinical facilities buy disinfection systems and services for patient rooms, equipment, and high-touch areas.

Life sciences and laboratories

Labs and research facilities use the technology to reduce contamination risk in controlled environments.

Pharmaceutical and biotech

Manufacturers and cleanroom operators buy decontamination solutions to support sterile operations.

Food and beverage

Processors and related facilities use sanitation solutions to support hygiene and compliance.

Commercial and institutional

Schools, offices, transportation, and other public venues may purchase disinfection systems or services.

Strategia

TOMI's strategy is centered on commercializing its proprietary disinfection platform across regulated and contamination-sensitive end markets. The company relies on expanding installed usage, broadening customer adoption, and supporting recurring demand through consumables, service work, and application support.

Commercialize proprietary disinfection technologyLyhyt aikaväli

A differentiated technology platform can support customer adoption and pricing power versus commodity cleaning products.

Increase recurring revenue mixKeskipitkä aikaväli

Consumables and service work can create repeat demand after initial system placement.

Expand into regulated end marketsKeskipitkä aikaväli

Healthcare, labs, and pharma customers have persistent contamination-control needs and higher switching costs.

Maantiede

Q1/2026

The company is based in the United States and serves domestic customers as well as international markets through commercial sales and distribution relationships. Geography matters because adoption of disinfection technology depends on local regulatory standards, customer budgets, and the presence of healthcare and industrial end markets.

Other countries (US filing)100 %

Riskit

TOMI depends on customer adoption of a specialized technology platform, so demand can be uneven and tied to capital spending cycles in healthcare and industrial end markets. The company also faces execution risk in scaling sales, supporting installations, and converting interest in disinfection technology into repeatable revenue, while broader risks include competition from alternative sanitation methods and regulatory or validation requirements.

Järjestetty vakavuuden mukaan
Small-company execution riskKorkea

A niche commercial model requires effective sales, installation, and service execution to convert pipeline into revenue.

Kohdistuu: Company-wide

Customer adoption and demand variabilityKorkea

The business depends on customers choosing a specialized disinfection platform rather than standard cleaning or competing technologies.

KohdistuuHealthcareLabsPharmaFood safety
Competitive substitutionKeskitaso

Alternative disinfectants, UV systems, and contract cleaning providers can reduce demand for TOMI's systems and services.

Kohdistuu: All end markets

Regulatory and validation burdenKeskitaso

Customers in regulated environments often require proof of efficacy and compliance before adoption.

Kohdistuu: Healthcare and life sciences

Kirjanpito

Harkinnanvaraiset erät
Revenue recognition by product and service type

System sales, consumables, and decontamination services may be recognized at different points in time, affecting quarterly comparability.

Vaikutus: Reported revenue mix and timing

Convertible promissory notes

The 2025 private placement notes include conversion features and interest, which may require separate accounting treatment and valuation judgments.

Vaikutus: Debt balance, interest expense, and potential dilution

Allowance for doubtful accounts

A small customer base and project-based sales can increase credit risk and require reserves.

Vaikutus: Net revenue and receivables

Inventory and equipment valuation

Specialized systems and components may need write-downs if demand or obsolescence changes.

Vaikutus: Gross margin and asset values

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Päivitetty: 24.9.2026